Jing-Ping Liou

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4203612/publications.pdf

Version: 2024-02-01

124	4,199	94381	138417
papers	citations	37 h-index	58 g-index

132	132	132	5520
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Nitro-Group-Containing Drugs. Journal of Medicinal Chemistry, 2019, 62, 2851-2893.	2.9	356
2	BPR0L075, a Novel Synthetic Indole Compound with Antimitotic Activity in Human Cancer Cells, Exerts Effective Antitumoral Activity in Vivo. Cancer Research, 2004, 64, 4621-4628.	0.4	193
3	Concise Synthesis and Structureâ^'Activity Relationships of Combretastatin A-4 Analogues, 1-Aroylindoles and 3-Aroylindoles, as Novel Classes of Potent Antitubulin Agents. Journal of Medicinal Chemistry, 2004, 47, 4247-4257.	2.9	151
4	Synthesis and Structureâ^'Activity Relationship of 2-Aminobenzophenone Derivatives as Antimitotic Agents. Journal of Medicinal Chemistry, 2002, 45, 2556-2562.	2.9	112
5	Idiopathic Pulmonary Fibrosis: Current Status, Recent Progress, and Emerging Targets. Journal of Medicinal Chemistry, 2017, 60, 527-553.	2.9	103
6	Recent developments in epigenetic cancer therapeutics: clinical advancement and emerging trends. Journal of Biomedical Science, 2021, 28, 27.	2.6	103
7	Synthesis and Structureâ^'Activity Relationships of 3-Aminobenzophenones as Antimitotic Agents. Journal of Medicinal Chemistry, 2004, 47, 2897-2905.	2.9	90
8	Synthesis and Evaluation of 3-Aroylindoles as Anticancer Agents: Metabolite Approach. Journal of Medicinal Chemistry, 2009, 52, 4941-4945.	2.9	84
9	Histone deacetylase inhibition improved cardiac functions with direct antifibrotic activity in heart failure. International Journal of Cardiology, 2013, 168, 4178-4183.	0.8	82
10	Tubulin inhibitors: a patent review. Expert Opinion on Therapeutic Patents, 2014, 24, 69-88.	2.4	78
11	Antitubulin agents for the treatment of cancer â€“ a medicinal chemistry update. Expert Opinion on Therapeutic Patents, 2006, 16, 647-691.	2.4	76
12	7-Aroyl-aminoindoline-1-sulfonamides as a Novel Class of Potent Antitubulin Agents. Journal of Medicinal Chemistry, 2006, 49, 6656-6659.	2.9	69
13	5-Amino-2-Aroylquinolines as Highly Potent Tubulin Polymerization Inhibitors. Journal of Medicinal Chemistry, 2010, 53, 2309-2313.	2.9	69
14	The synergic effect of vincristine and vorinostat in leukemia in vitro and in vivo. Journal of Hematology and Oncology, 2015, 8, 82.	6.9	69
15	(N-Hydroxycarbonylbenylamino)quinolines as Selective Histone Deacetylase 6 Inhibitors Suppress Growth of Multiple Myeloma in Vitro and in Vivo. Journal of Medicinal Chemistry, 2018, 61, 905-917.	2.9	69
16	Discovery of 4-Amino and 4-Hydroxy-1-aroylindoles as Potent Tubulin Polymerization Inhibitors. Journal of Medicinal Chemistry, 2008, 51, 4351-4355.	2.9	68
17	The novel histone de acetylase 6 inhibitor, MPT0G211, ameliorates tau phosphorylation and cognitive deficits in an Alzheimerâ€™s disease model. Cell Death and Disease, 2018, 9, 655.	2.7	68
18	Azaindolylsulfonamides, with a More Selective Inhibitory Effect on Histone Deacetylase 6 Activity, Exhibit Antitumor Activity in Colorectal Cancer HCT116 Cells. Journal of Medicinal Chemistry, 2014, 57, 4009-4022.	2.9	66

#	Article	IF	Citations
19	Increased activation of HDAC1/2/6 and Sp1 underlies therapeutic resistance and tumor growth in glioblastoma. Neuro-Oncology, 2020, 22, 1439-1451.	0.6	63
20	Specificity protein 1-modulated superoxide dismutase 2 enhances temozolomide resistance in glioblastoma, which is independent of O6-methylguanine-DNA methyltransferase. Redox Biology, 2017, 13, 655-664.	3.9	60
21	A Novel Oral Indoline-Sulfonamide Agent, N-[1-(4-Methoxybenzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-Isonicotinamide (J30), Exhibits Potent Activity against Human Cancer Cells in Vitro and in Vivo through the Disruption of Microtubule. Journal of Pharmacology and Experimental Therapeutics, 2007, 323, 398-405.	1.3	57
22	Hypoxia-Induced Downregulation of DUSP-2 Phosphatase Drives Colon Cancer Stemness. Cancer Research, 2017, 77, 4305-4316.	0.4	56
23	5-Aroylindoles Act as Selective Histone Deacetylase 6 Inhibitors Ameliorating Alzheimerâ€™s Disease Phenotypes. Journal of Medicinal Chemistry, 2018, 61, 7087-7102.	2.9	56
24	4- and 5-Aroylindoles as Novel Classes of Potent Antitubulin Agents. Journal of Medicinal Chemistry, 2007, 50, 4548-4552.	2.9	54
25	Synthesis and Biological Evaluation of 1-Arylsulfonyl-5-(N-hydroxyacrylamide)indoles as Potent Histone Deacetylase Inhibitors with Antitumor Activity in Vivo. Journal of Medicinal Chemistry, 2012, 55, 3777-3791.	2.9	52
26	Recent Update of HDAC Inhibitors in Lymphoma. Frontiers in Cell and Developmental Biology, 2020, 8, 576391.	1.8	48
27	Androgen attenuates cardiac fibroblasts activations through modulations of transforming growth factor-Î² and angiotensin II signaling. International Journal of Cardiology, 2014, 176, 386-393.	0.8	47
28	2-Amino and 2â€˜-Aminocombretastatin Derivatives as Potent Antimitotic Agents. Journal of Medicinal Chemistry, 2006, 49, 6412-6415.	2.9	46
29	Denbinobin upregulates miR-146a expression and attenuates IL-1Î²-induced upregulation of ICAM-1 and VCAM-1 expressions in osteoarthritis fibroblast-like synoviocytes. Journal of Molecular Medicine, 2014, 92, 1147-1158.	1.7	46
30	5-Amino-2-aroylquinolines as Highly Potent Tubulin Polymerization Inhibitors. Part 2. The Impact of Bridging Groups at Position C-2. Journal of Medicinal Chemistry, 2011, 54, 8517-8525.	2.9	45
31	Structureâ€“Activity Relationship Studies of 3-Aroylindoles as Potent Antimitotic Agents. ChemMedChem, 2006, 1, 1106-1118.	1.6	44
32	Synergistic Interaction between the HDAC Inhibitor, MPT0E028, and Sorafenib in Liver Cancer Cells In Vitro and In Vivo. Clinical Cancer Research, 2014, 20, 1274-1287.	3.2	44
33	Dual Inhibition of PIK3C3 and FGFR as a New Therapeutic Approach to Treat Bladder Cancer. Clinical Cancer Research, 2018, 24, 1176-1189.	3.2	43
34	Ocular Disease Therapeutics: Design and Delivery of Drugs for Diseases of the Eye. Journal of Medicinal Chemistry, 2020, 63, 10533-10593.	2.9	43
35	1-Aroylindoline-hydroxamic acids as anticancer agents, inhibitors of HSP90 and HDAC. European Journal of Medicinal Chemistry, 2018, 150, 667-677.	2.6	42
36	Indole-3-ethylsulfamoylphenylacrylamides: Potent histone deacetylase inhibitors with anti-inflammatory activity. European Journal of Medicinal Chemistry, 2014, 85, 468-479.	2.6	41

#	Article	IF	Citations
37	N-alkyl-hydroxybenzoyl anilide hydroxamates as dual inhibitors of HDAC and HSP90, downregulating IFN-Î³ induced PD-L1 expression. European Journal of Medicinal Chemistry, 2020, 185, 111725.	2.6	41
38	Furanylazaindoles: Potent Anticancer Agents in Vitro and in Vivo. Journal of Medicinal Chemistry, 2013, 56, 8008-8018.	2.9	40
39	Suberoylanilide hydroxamic acid represses glioma stem-like cells. Journal of Biomedical Science, 2016, 23, 81.	2.6	34
40	3-Aroylindoles display antitumor activity inÂvitro and inÂvivo: Effects of N1-substituents on biological activity. European Journal of Medicinal Chemistry, 2017, 125, 1268-1278.	2.6	34
41	Purine/purine isoster based scaffolds as new derivatives of benzamide class of HDAC inhibitors. European Journal of Medicinal Chemistry, 2020, 196, 112291.	2.6	33
42	1-Arylsulfonyl indoline-benzamides as a new antitubulin agents, with inhibition of histone deacetylase. European Journal of Medicinal Chemistry, 2019, 162, 612-630.	2.6	32
43	Anti-metastatic activity of MPT0G211, a novel HDAC6 inhibitor, in human breast cancer cells in vitro and in vivo. Biochimica Et Biophysica Acta - Molecular Cell Research, 2019, 1866, 992-1003.	1.9	31
44	A novel class I HDAC inhibitor, MPT0G030, induces cell apoptosis and differentiation in human colorectal cancer cells via HDAC1/PKCÎ´ and E-cadherin. Oncotarget, 2014, 5, 5651-5662.	0.8	31
45	Synthesis and biological evaluation of 1-(4â€²-Indolyl and 6â€²-Quinolinyl) indoles as a new class of potent anticancer agents. European Journal of Medicinal Chemistry, 2011, 46, 3623-3629.	2.6	30
46	Intermediary Metabolite Precursor Dimethyl-2-Ketoglutarate Stabilizes Hypoxia-Inducible Factor-1Î± by Inhibiting Prolyl-4-Hydroxylase PHD2. PLoS ONE, 2014, 9, e113865.	1.1	30
47	Synthesis and Structureâ^'Activity Relationships of 2-Amino-1-aroylnaphthalene and 2-Hydroxy-1-aroylnaphthalenes as Potent Antitubulin Agents. Journal of Medicinal Chemistry, 2008, 51, 8163-8167.	2.9	29
48	MPT0B098, a Microtubule Inhibitor, Suppresses JAK2/STAT3 Signaling Pathway through Modulation of SOCS3 Stability in Oral Squamous Cell Carcinoma. PLoS ONE, 2016, 11, e0158440.	1.1	29
49	Early investigational tubulin inhibitors as novel cancer therapeutics. Expert Opinion on Investigational Drugs, 2016, 25, 917-936.	1.9	28
50	2-(Phenylsulfonyl)quinoline N -hydroxyacrylamides as potent anticancer agents inhibiting histone deacetylase. European Journal of Medicinal Chemistry, 2016, 122, 92-101.	2.6	28
51	MPT0G612, a Novel HDAC6 Inhibitor, Induces Apoptosis and Suppresses IFN-Î³-Induced Programmed Death-Ligand 1 in Human Colorectal Carcinoma Cells. Cancers, 2019, 11, 1617.	1.7	28
52	Anticancer activity of MPT0G157, a derivative of indolylbenzenesulfonamide, inhibits tumor growth and angiogenesis. Oncotarget, 2015, 6, 18590-18601.	0.8	26
53	N-Sulfonyl-aminobiaryls as Antitubulin Agents and Inhibitors of Signal Transducers and Activators of Transcription 3 (STAT3) Signaling. Journal of Medicinal Chemistry, 2015, 58, 6549-6558.	2.9	26
54	Isoindoline scaffold-based dual inhibitors of HDAC6 and HSP90 suppressing the growth of lung cancer inÂvitro and inÂvivo. European Journal of Medicinal Chemistry, 2020, 190, 112086.	2.6	25

#	Article	IF	Citations
55	Anticancer Activity of MPT0E028, a Novel Potent Histone Deacetylase Inhibitor, in Human Colorectal Cancer HCT116 Cells In Vitro and In Vivo. PLoS ONE, 2012, 7, e43645.	1.1	24
56	TIMP3 expression associates with prognosis in colorectal cancer and its novel arylsulfonamide inducer, MPT0B390, inhibits tumor growth, metastasis and angiogenesis. Theranostics, 2019, 9, 6676-6689.	4.6	24
57	Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status. Clinical Epigenetics, 2019, 11, 85.	1.8	24
58	CAP rigidification of MS-275 and chidamide leads to enhanced antiproliferative effects mediated through HDAC1, 2 and tubulin polymerization inhibition. European Journal of Medicinal Chemistry, 2021, 215, 113169.	2.6	23
59	Synthesis and biological evaluation of 7-arylindoline-1-benzenesulfonamides as a novel class of potent anticancer agents. MedChemComm, 2010, 1, 152.	3.5	22
60	A Novel Dual HDAC6 and Tubulin Inhibitor, MPT0B451, Displays Anti-tumor Ability in Human Cancer Cells in Vitro and in Vivo. Frontiers in Pharmacology, 2018, 9, 205.	1.6	22
61	1â€Arylsulfonylâ€5â€(Nâ€hydroxyacrylamide)indolines Histone Deacetylase Inhibitors Are Potent Cytokine Release Suppressors. ChemBioChem, 2013, 14, 1248-1254.	1.3	21
62	4-Indolyl- N -hydroxyphenylacrylamides as potent HDAC class I and IIB inhibitors inÂvitro and inÂvivo. European Journal of Medicinal Chemistry, 2017, 134, 13-23.	2.6	21
63	Concise syntheses of N-aryl-5,6,7-trimethoxyindoles as antimitotic and vascular disrupting agents: application of the copper-mediated Ullmann-type arylation. Organic and Biomolecular Chemistry, 2011, 9, 3154.	1.5	20
64	1-Arylsulfonyl-5-(N-hydroxyacrylamide)tetrahydroquinolines as potent histone deacetylase inhibitors suppressing the growth of prostate cancer cells. European Journal of Medicinal Chemistry, 2015, 89, 320-330.	2.6	20
65	Ring-opened tetrahydro-Î³-carbolines display cytotoxicity and selectivity with histone deacetylase isoforms. European Journal of Medicinal Chemistry, 2017, 127, 115-127.	2.6	20
66	The anticancer effects of MPT0G211, a novel HDAC6 inhibitor, combined with chemotherapeutic agents in human acute leukemia cells. Clinical Epigenetics, 2018, 10, 162.	1.8	20
67	Novel histone deacetylase inhibitor MPT0G009 induces cell apoptosis and synergistic anticancer activity with tumor necrosis factor-related apoptosis-inducing ligand against human hepatocellular carcinoma. Oncotarget, 2016, 7, 402-417.	0.8	19
68	MPT0G413, A Novel HDAC6-Selective Inhibitor, and Bortezomib Synergistically Exert Anti-tumor Activity in Multiple Myeloma Cells. Frontiers in Oncology, 2019, 9, 249.	1.3	18
69	Trichlorobenzene-substituted azaaryl compounds as novel FGFR inhibitors exhibiting potent antitumor activity in bladder cancer cells in vitro and in vivo. Oncotarget, 2016, 7, 26374-26387.	0.8	18
70	Upregulation of Znf179 acetylation by SAHA protects cells against oxidative stress. Redox Biology, 2018, 19, 74-80.	3.9	17
71	MPT0B169, a New Tubulin Inhibitor, Inhibits Cell Growth and Induces G2/M Arrest in Nonresistant and Paclitaxel-Resistant Cancer Cells. Pharmacology, 2013, 92, 90-98.	0.9	15
72	Histone deacetylase inhibitor MPT0B291 suppresses Glioma Growth in vitro and in vivo partially through acetylation of p53. International Journal of Biological Sciences, 2020, 16, 3184-3199.	2.6	15

#	Article	IF	Citations
73	A novel dual HDAC and HSP90 inhibitor, MPT0G449, downregulates oncogenic pathways in human acute leukemia in vitro and in vivo. Oncogenesis, 2021, 10, 39.	2.1	15
74	Installation of Pargyline, a LSD1 Inhibitor, in the HDAC Inhibitory Template Culminated in the Identification of a Tractable Antiprostate Cancer Agent. Journal of Medicinal Chemistry, 2021, 64, 17824-17845.	2.9	15
75	Antimitotic and antivascular activity of heteroaroyl-2-hydroxy-3,4,5-trimethoxybenzenes. Bioorganic and Medicinal Chemistry, 2015, 23, 4230-4236.	1.4	14
76	1,4-Naphthoquinones as inhibitors of Itch, a HECT domain-E3 ligase, and tumor growth suppressors in multiple myeloma. European Journal of Medicinal Chemistry, 2017, 140, 84-91.	2.6	14
77	Histone lysine specific demethylase 1 inhibitors. RSC Medicinal Chemistry, 2020, 11, 969-981.	1.7	14
78	Suppression of Extracellular Vesicle VEGF-Câ€“mediated Lymphangiogenesis and Pancreatic Cancer Early Dissemination By a Selective HDAC1/2 Inhibitor. Molecular Cancer Therapeutics, 2021, 20, 1550-1560.	1.9	14
79	Novel oral histone deacetylase inhibitor, MPT0E028, displays potent growth-inhibitory activity against human B-cell lymphomain vitroandin vivo. Oncotarget, 2015, 6, 4976-4991.	0.8	14
80	Curcumin Suppress Cardiac Fibroblasts Activities by Regulating Proliferation, Migration, and the Extracellular Matrix. Acta Cardiologica Sinica, 2014, 30, 474-82.	0.1	14
81	HDAC6 involves in regulating the lncRNA-microRNA-mRNA network to promote the proliferation of glioblastoma cells. Journal of Experimental and Clinical Cancer Research, 2022, 41, 47.	3.5	14
82	Synthesis and Structureâ€“Activity Relationships of 1â€Benzylâ€4,5,6â€trimethoxyindoles as a Novel Class of Potent Antimitotic Agents. ChemMedChem, 2009, 4, 588-593.	1.6	13
83	Amide-tethered quinoline-resorcinol conjugates as a new class of HSP90 inhibitors suppressing the growth of prostate cancer cells. Bioorganic Chemistry, 2019, 91, 103119.	2.0	13
84	HDAC inhibitor protects chronic cerebral hypoperfusion and oxygenâ€glucose deprivation injuries via H3K14 and H4K5 acetylationâ€mediated BDNF expression. Journal of Cellular and Molecular Medicine, 2020, 24, 6966-6977.	1.6	13
85	Pragmatic recruitment of memantine as the capping group for the design of HDAC inhibitors: A preliminary attempt to unravel the enigma of glioblastoma. European Journal of Medicinal Chemistry, 2021, 217, 113338.	2.6	13
86	Pyrimidinedione-mediated selective histone deacetylase 6 inhibitors with antitumor activity in colorectal cancer HCT116 cells. Organic and Biomolecular Chemistry, 2015, 13, 10226-10235.	1.5	12
87	MPT0G066, a novel anti-mitotic drug, induces JNK-independent mitotic arrest, JNK-mediated apoptosis and potentiates antineoplastic effect of cisplatin in ovarian cancer. Scientific Reports, 2016, 6, 31664.	1.6	12
88	Targeting Autophagy by MPT0L145, a Highly Potent PIK3C3 Inhibitor, Provides Synergistic Interaction to Targeted or Chemotherapeutic Agents in Cancer Cells. Cancers, 2019, 11, 1345.	1.7	12
89	2â€Aminoâ€3,4,5â€Trimethoxybenzophenones as Potent Tubulin Polymerization Inhibitors. ChemMedChem, 2011, 6, 450-456.	1.6	11
90	Protective effects of 10,11-dihydro-5H-dibenzo[b,f]azepine hydroxamates on vascular cognitive impairment. European Journal of Medicinal Chemistry, 2020, 187, 111915.	2.6	11

#	Article	IF	Citations
91	A novel action mechanism for MPT0G013, a derivative of arylsulfonamide, inhibits tumor angiogenesis through up-regulation of TIMP3 expression. Oncotarget, 2014, 5, 9838-9850.	0.8	11
92	Concise syntheses of 7-anilino-indoline-N-benzenesulfonamides as antimitotic and vascular disrupting agents. Bioorganic and Medicinal Chemistry, 2014, 22, 4917-4923.	1.4	10
93	Novel microtubule inhibitor MPT0B098 inhibits hypoxia-induced epithelial-to-mesenchymal transition in head and neck squamous cell carcinoma. Journal of Biomedical Science, 2018, 25, 28.	2.6	10
94	Histone deacetylase 6 acts upstream of DNA damage response activation to support the survival of glioblastoma cells. Cell Death and Disease, 2021, 12, 884.	2.7	10
95	CK1Î´ as a potential therapeutic target to treat bladder cancer. Aging, 2020, 12, 5764-5780.	1.4	10
96	N-Methylpropargylamine-Conjugated Hydroxamic Acids as Dual Inhibitors of Monoamine Oxidase A and Histone Deacetylase for Glioma Treatment. Journal of Medicinal Chemistry, 2022, 65, 2208-2224.	2.9	10
97	Antiangiogenic activities and cisplatin-combined antitumor activities of BPR0L075. Anticancer Research, 2010, 30, 2813-22.	0.5	10
98	Effect of C7-substitution of 1-arylsulfonyl-5-(N-hydroxyacrylamide)indolines on the selectivity towards a subclass of histone deacetylases. Organic and Biomolecular Chemistry, 2014, 12, 8966-8976.	1.5	9
99	LTP-1, a novel antimitotic agent and Stat3 inhibitor, inhibits human pancreatic carcinomas in vitro and in vivo. Scientific Reports, 2016, 6, 27794.	1.6	9
100	Total Synthesis of Denbinobin. Journal of Natural Products, 2016, 79, 1170-1173.	1.5	9
101	2-Aroylquinoline-5,8-diones as potent anticancer agents displaying tubulin and heat shock protein 90 (HSP90) inhibition. Organic and Biomolecular Chemistry, 2016, 14, 716-723.	1.5	9
102	Identification of 7-(4â€²-Cyanophenyl)indoline-1-benzenesulfonamide as a mitotic inhibitor to induce apoptotic cell death and inhibit autophagy in human colorectal cancer cells. Scientific Reports, 2017, 7, 12406.	1.6	9
103	Synthesis and evaluation of novel 7H-pyrrolo-[2,3-d]pyrimidine derivatives as potential anticancer agents. Future Medicinal Chemistry, 2019, 11, 959-974.	1.1	9
104	Design, synthesis, and evaluation of N-phenyl-4-(2-phenylsulfonamido)-benzamides as microtubule-targeting agents in drug-resistant cancer cells, displaying HDAC inhibitory response. European Journal of Medicinal Chemistry, 2020, 192, 112158.	2.6	9
105	Ring-opening of five-membered heterocycles conjugated 4-isopropylresorcinol scaffold-based benzamides as HSP90 inhibitors suppressing tumor growth inÂvitro and inÂvivo. European Journal of Medicinal Chemistry, 2021, 219, 113428.	2.6	9
106	Rational design of synthetically tractable HDAC6/HSP90 dual inhibitors to destroy immune-suppressive tumor microenvironment. Journal of Advanced Research, 2023, 46, 159-171.	4.4	9
107	Antimitotic and vascular disrupting agents: 2-Hydroxy-3,4,5-trimethoxybenzophenones. European Journal of Medicinal Chemistry, 2014, 77, 306-314.	2.6	8
108	Optimization and Development of Selective Histone Deacetylase Inhibitor (MPT0B291)-Loaded Albumin Nanoparticles for Anticancer Therapy. Pharmaceutics, 2021, 13, 1728.	2.0	8

#	Article	IF	Citations
109	A novel tubulin polymerization inhibitor, MPT0B206, downregulates Bcr-Abl expression and induces apoptosis in imatinib-sensitive and imatinib-resistant CML cells. Apoptosis: an International Journal on Programmed Cell Death, 2016, 21, 1008-1018.	2.2	7
110	MPT0B169, a novel tubulin inhibitor, induces apoptosis in taxol-resistant acute myeloid leukemia cells through mitochondrial dysfunction and Mcl-1 downregulation. Tumor Biology, 2016, 37, 6065-6072.	0.8	7
111	Total Synthesis of Two Glycosylated Stilbenes, Oxyresveratrol 2-O-Î²-<scp>d</scp>-Glucopyranoside and 2,3,5,4â€²-Tetrahydroxystilbene 2-O-Î²-<scp>d</scp>-Glucopyranoside. Journal of Natural Products, 2017, 80, 1294-1301.	1.5	7
112	Fluoropyrimidin-2,4-dihydroxy-5-isopropylbenzamides as antitumor agents against CRC and NSCLC cancer cells. European Journal of Medicinal Chemistry, 2020, 203, 112540.	2.6	6
113	Anaplastic lymphoma kinase inhibitors: an updated patent review (2014â€“2018). Expert Opinion on Therapeutic Patents, 2020, 30, 351-373.	2.4	6
114	An oral quinoline derivative, MPT0B392, causes leukemic cells mitotic arrest and overcomes drug resistant cancer cells. Oncotarget, 2017, 8, 27772-27785.	0.8	6
115	Molecular mechanisms underlying the antitumor activity of (E)-N-hydroxy-3-(1-(4-methoxyphenylsulfonyl)-1,2,3,4-tetrahydroquinolin-6-yl)acrylamide in human colorectal cancer cells in vitro and in vivo. Oncotarget, 2015, 6, 35991-36002.	0.8	6
116	MPT0B002, a novel microtubule inhibitor, downregulates T315I mutant Bcr-Abl and induces apoptosis of imatinib-resistant chronic myeloid leukemia cells. Investigational New Drugs, 2017, 35, 427-435.	1.2	5
117	Indole-3-ethylsulfamoylphenylacrylamides with Potent Anti-proliferative and Anti-angiogenic Activities. Anti-Cancer Agents in Medicinal Chemistry, 2016, 16, 907-913.	0.9	5
118	Anti-leukemia effects of the novel synthetic 1-benzylindole derivative 21-900 in vitro and in vivo. Scientific Reports, 2017, 7, 42291.	1.6	4
119	Synthesis and biological evaluation of 2-quinolineacrylamides. Bioorganic and Medicinal Chemistry, 2020, 28, 115250.	1.4	4
120	Effect of 3-subsitution of quinolinehydroxamic acids on selectivity of histone deacetylase isoforms. Journal of Enzyme Inhibition and Medicinal Chemistry, 2021, 36, 74-84.	2.5	4
121	A novel histone deacetylase inhibitor MPT0L184 dysregulates cell-cycle checkpoints and initiates unscheduled mitotic signaling. Biomedicine and Pharmacotherapy, 2021, 138, 111485.	2.5	4
122	Combining an Autophagy Inhibitor, MPT0L145, with Abemaciclib Is a New Therapeutic Strategy in GBM Treatment. Cancers, 2021, 13, 6117.	1.7	4
123	Synthesis and Biological Evaluation of 4-Aroyl-6,7,8-Trimethoxyquinolines as a Novel Class of Anticancer Agents. Molecules, 2011, 16, 2274-2284.	1.7	3
124	Pharmacokinetics and protein binding of MPT0B292. Biopharmaceutics and Drug Disposition, 2017, 38, 340-350.	1.1	0